BC Extra | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

Label expansion for Novo’s Ozempic  FDA approved Ozempic subcutaneous semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NOVO) to reduce the risk of major adverse cardiovascular events in adults with Type II diabetes and heart disease....
BC Extra | Jan 4, 2020
Company News

Management tracks: Fountain Medical taps Zhen as CEO; plus DBV, Momenta reveal CFO succession plans

Fountain Medical Development Ltd. named Ling Zhen as CEO and co-chairman. Zhen joins the clinical CRO from Draper Dragon Venture Group, where he was a partner focused on biopharmaceutical and medical technology investments. Zhen is...
BC Extra | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

Momenta, Forty Seven and Assembly joined the year-end push for follow-on stock offerings, raising an aggregate of $520 million. The financings bring this year’s tally for follow-ons to about $21.5 billion, well short of 2018’s...
BC Extra | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

December’s rush of follow-ons has continued with Rocket, Constellation and Marinus all pricing follow-on offerings since Tuesday’s close to raise more than $340 million. But cash raised via follow-ons continues to lag behind last year's...
BioCentury | Jun 21, 2019
Politics, Policy & Law

Fearmongering about China diminishes American life sciences competitiveness

No country has ever spied its way into technological superiority. The Soviet Union tried mightily and failed miserably. This lesson is relevant at a time when members of Congress are making unsubstantiated allegations about Chinese...
BC Innovations | Jun 5, 2019

Conflicts over scale, response to foreign threats and espionage against NIH research at Senate hearing

A June 5 Senate Finance Committee hearing saw sparks fly over allegations of spying, with two Republican senators accusing the Chinese government of engaging in large-scale espionage against U.S. taxpayer-funded research, and a Democrat countering...
BC Extra | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin...
BC Extra | May 24, 2019
Company News

CFIUS influence may have prompted Momenta's restructuring

As biotech’s concerns over trade tensions between the U.S. and China intensify, details have come to light of a biopharma deal derailed by stricter CFIUS regulations. The scuttled deal may have contributed to Momenta's decision...
BC Week In Review | Feb 7, 2019
Clinical News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Feb. 1, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I...
BC Week In Review | Dec 14, 2018
Financial News

Momenta, Global Blood price follow-ons

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Global Blood Therapeutics Inc. (NASDAQ:GBT) each priced follow-ons, raising a total of $350 million. Momenta raised $200 million Dec. 6 through the sale of 17.4 million shares at $11.50. The...
Items per page:
1 - 10 of 431